EDIT

Editas MedicineB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$4.80

+70.2% vs current

Most likely

Base case

45%

Probability

Target price

$3.10

+9.9% vs current

B-

Bear case

30%

Probability

Target price

$1.90

-32.6% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Sentiment is cautious rather than constructive. Primary-source evidence supports real 2026 milestones and a runway claim into the third quarter of 2027, but the thesis is still mostly a monitoring view because forward value realization depends on one in vivo program and several execution gates in close succession [#PR-2026-03-09] [#8-K-2026-04-07]. Given the negative deterministic prior, moderate uncertainty, and loose peer set, the stock looks more like a watchlist event name than a high-conviction long today.

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-15catalystFirst periodic filing after auditor change tests control and disclosure confidenceHigh impact

The April 7, 2026 8-K disclosed a switch from Ernst & Young to PwC effective April 1, 2026 and stated there were no disagreements or reportable events [#8-K-2026-04-07]. The next periodic filing is a practical checkpoint for whether the transition stays non-disruptive and whether investors can move past the governance headline.

2026-06-30eventEDIT-401 IND/CTA filing and mid-2026 preclinical updateHigh impact

Management said EDIT-401 remains on track for additional preclinical data and IND/CTA submission by mid-2026, making regulatory readiness the clearest near-term proof point for the in vivo strategy [#PR-2026-03-09]. A slip here would likely reinforce the current negative prior for a single-lead, small-cap biotech.

2026-12-15catalystFirst-in-human EDIT-401 start and early proof-of-concept windowHigh impact

Editas said it is preparing to start its first-in-human HeFH study later in 2026 and still expects early human proof-of-concept by year-end 2026, with dose-finding topline data in 2027 [#PR-2026-03-09]. Because the company is now centered on one lead in vivo program, execution here is the main determinant of whether valuation can re-rate beyond cash-runway support.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology